Sarcopenia and its impact in head and neck cancer treatment
Remco de Bree, Maartje A. van Beers, Anouk W. M. A. Schaeffers, MS Hoofd-Hals Chirurgische Oncologie, MS Hoofd-Hals Chirurgische Oncologie, Cancer
Abstract
PURPOSE OF REVIEW: The aim of this review is to discuss recent studies on the assessment of sarcopenia and its predictive and prognostic value in head and neck cancer (HNC) patients. RECENT FINDINGS: There is increasing evidence that low skeletal muscle mass (SMM), often named sarcopenia, can easily be assessed on cross-sectional imaging of the head and neck and is associated with chemotherapy (dose limiting) and radiotherapy toxicity and survival. SUMMARY: SMM measurement at the level of the third cervical vertebra (C3) on routine computed tomography and magnetic resonance imaging is easy and robust to perform. Several studies have shown a significantly higher incidence of cisplatin dose limiting toxicity in HNC patients with a low SMM. In HNC patients pretreatment low SMM is associated with acute and late toxicity and adverse events of radiotherapy, complications of major head and neck surgery and decreased disease-specific and overall survival. This information can be used for individualized treatment planning in HNC patients with low SMM.